AbbVie and the International Myeloma Foundation (IMF) have announced that they have entered into a collaboration to conduct a landmark retrospective chart review study to better understand and help manage multiple myeloma (MM), the second most common blood cancer.
The primary objective of the study is to determine the overall survival of patients with MM and the t(11;14) translocation, which is present in an estimated sixteen to twenty four percent of FISH-tested MM cases. IMF researchers from at least thirty participating sites across the world will retrospectively review and characterize the outcomes of 1,500 patients with the t(11;14) translocation identified on FISH, making this study one of the largest and most comprehensive MM studies to date. Secondary objectives include response rates, progression-free survival, time to progression, time to next treatment, duration of responses and overall survival with different regimens among patients with the t(11;14) translocation. Additional secondary objectives include determining prognostic factors for overall survival among MM patients with t(11;14) translocation and to identify the spectrum of co-existing genetic abnormalities among this patient population.
“There are significant knowledge gaps about multiple myeloma, and among these gaps is the role of genetic mutations in response to treatment, and the related outcomes for patients,” said Brian G.M. Durie, M.D., IMF chairman. “This study has the potential to provide valuable real-world evidence that can help advance care for patients, and we are proud to join forces with AbbVie to further advance efforts in research and education in multiple myeloma.”
Neil Gallagher, M.D., Ph.D., vice president and head, global oncology development, AbbVie said, “The partnership with the International Myeloma Foundation underscores our commitment to meaningfully advance the understanding of blood cancers, and continue identifying scientific approaches that have the potential to improve care for patients with multiple myeloma.”